Cardiff Oncology, Inc. financial data

Symbol
CRDF on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
11055 Flintkote Avenue, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Trovagene, Inc. (to 5/7/2020), TrovaGene Inc. (to 3/4/2013), XENOMICS INC (to 6/3/2009), USED KAR PARTS INC (to 6/30/2004)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 670 % -47.5%
Debt-to-equity 18.9 % +84.9%
Return On Equity -62.7 % -59.1%
Return On Assets -52.7 % -47.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.5M shares +4.19%
Common Stock, Shares, Outstanding 45.6M shares +2.07%
Entity Public Float 64.3M USD -31.4%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 44.8M shares +0.33%
Weighted Average Number of Shares Outstanding, Diluted 44.8M shares +0.33%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 665K USD +61.4%
Operating Income (Loss) -44.6M USD -4.66%
Nonoperating Income (Expense) 3.77M USD +25.6%
Net Income (Loss) Attributable to Parent -40.9M USD -3.07%
Earnings Per Share, Basic -0.91 USD/shares -1.11%
Earnings Per Share, Diluted -0.91 USD/shares -1.11%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.5M USD +31.7%
Cash, Cash Equivalents, and Short-term Investments 60.3M USD -32.6%
Accounts Receivable, after Allowance for Credit Loss, Current 451K USD +180%
Assets, Current 62.2M USD -32.9%
Property, Plant and Equipment, Net 1.1M USD -19.2%
Operating Lease, Right-of-Use Asset 1.44M USD -27.3%
Other Assets, Noncurrent 1.27M USD -8.56%
Assets 66.1M USD -32.2%
Accounts Payable, Current 5.11M USD +73.8%
Employee-related Liabilities, Current 1.79M USD -17.7%
Accrued Liabilities, Current 6.71M USD +22%
Liabilities, Current 12.5M USD +37.3%
Operating Lease, Liability, Noncurrent 1.14M USD -34.9%
Liabilities 13.7M USD +25.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -97K USD +77.5%
Retained Earnings (Accumulated Deficit) -361M USD -12.5%
Stockholders' Equity Attributable to Parent 52.4M USD -39.5%
Liabilities and Equity 66.1M USD -32.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.74M USD +10.6%
Net Cash Provided by (Used in) Financing Activities 107K USD
Net Cash Provided by (Used in) Investing Activities 4.64M USD -36.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 45.6M shares +2.07%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3M USD -125%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.5M USD +31.7%
Deferred Tax Assets, Valuation Allowance 39.2M USD +30.2%
Deferred Tax Assets, Gross 39.5M USD +29.3%
Operating Lease, Liability 2.15M USD -20.8%
Payments to Acquire Property, Plant, and Equipment 80K USD +900%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.5M USD -3.67%
Lessee, Operating Lease, Liability, to be Paid 2.4M USD -23.6%
Property, Plant and Equipment, Gross 5.05M USD +2.77%
Operating Lease, Liability, Current 702K USD +2.78%
Lessee, Operating Lease, Liability, to be Paid, Year Two 775K USD +2.79%
Lessee, Operating Lease, Liability, to be Paid, Year One 691K USD +2.22%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 249K USD -41%
Lessee, Operating Lease, Liability, to be Paid, Year Three 796K USD +2.71%
Deferred Tax Assets, Operating Loss Carryforwards 23.4M USD +15.5%
Preferred Stock, Shares Authorized 20M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 136K USD -82.9%
Operating Lease, Payments 730K USD +1.96%
Additional Paid in Capital 413M USD +1.36%
Depreciation, Depletion and Amortization 102K USD +13.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.17M USD -11.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%